Published in Cancer Res on July 01, 2005
An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell (2009) 10.09
Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One (2008) 8.97
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res (2009) 7.98
Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res (2008) 7.65
Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 6.38
CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res (2006) 6.35
Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A (2011) 5.53
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest (2007) 4.71
The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res (2008) 4.63
Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A (2008) 4.60
Cancer stem cells: an evolving concept. Nat Rev Cancer (2012) 4.57
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med (2011) 4.25
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest (2010) 4.22
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov (2009) 4.12
Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One (2008) 3.36
Unravelling cancer stem cell potential. Nat Rev Cancer (2013) 3.06
Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res (2008) 2.96
Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One (2008) 2.90
Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol (2008) 2.87
Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res (2009) 2.80
Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res (2010) 2.77
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
Lipid Desaturation Is a Metabolic Marker and Therapeutic Target of Ovarian Cancer Stem Cells. Cell Stem Cell (2016) 2.69
CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer (2008) 2.58
EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell (2011) 2.54
Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc Natl Acad Sci U S A (2010) 2.46
In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst (2009) 2.39
Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest (2010) 2.38
Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res (2012) 2.24
Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One (2010) 2.15
IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci U S A (2007) 2.09
Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res (2009) 2.04
Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res (2010) 1.96
Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis (2009) 1.94
CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer (2008) 1.93
Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One (2008) 1.90
p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci U S A (2009) 1.89
Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst (2010) 1.89
Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS One (2011) 1.87
Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One (2009) 1.82
Cancer stem cells in breast: current opinion and future challenges. Pathobiology (2008) 1.77
Spherical cancer models in tumor biology. Neoplasia (2015) 1.75
The human airway epithelial basal cell transcriptome. PLoS One (2011) 1.69
TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res (2011) 1.65
Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. Neoplasia (2007) 1.62
Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis. Cancer Lett (2009) 1.59
Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol (2013) 1.59
SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype. BMC Cancer (2010) 1.56
Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle (2009) 1.56
High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One (2010) 1.54
Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest (2012) 1.53
Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest (2010) 1.52
The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell (2012) 1.50
Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity. Breast Cancer Res (2011) 1.50
The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am J Pathol (2008) 1.49
Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells. Oncogene (2012) 1.49
Epithelial to mesenchymal transition by TGFβ-1 induction increases stemness characteristics in primary non small cell lung cancer cell line. PLoS One (2011) 1.48
Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med (2007) 1.48
ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med (2011) 1.47
Acetylation and activation of STAT3 mediated by nuclear translocation of CD44. J Cell Biol (2009) 1.47
Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev (2010) 1.46
Telomeres and telomerase in normal and cancer stem cells. FEBS Lett (2010) 1.46
Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci U S A (2014) 1.43
Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol (2011) 1.43
Arsenic exposure transforms human epithelial stem/progenitor cells into a cancer stem-like phenotype. Environ Health Perspect (2010) 1.42
Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines. Breast Cancer Res (2009) 1.42
Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res (2007) 1.42
What Do We Learn from Spheroid Culture Systems? Insights from Tumorspheres Derived from Primary Colon Cancer Tissue. PLoS One (2016) 1.40
NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat (2007) 1.39
Breast cancer stem cells: tools and models to rely on. BMC Cancer (2009) 1.38
Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species. J Biol Chem (2011) 1.36
Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery. Br J Cancer (2010) 1.35
Targeting telomerase for cancer therapeutics. Br J Cancer (2008) 1.35
Correlation of umbilical cord blood hormones and growth factors with stem cell potential: implications for the prenatal origin of breast cancer hypothesis. Breast Cancer Res (2007) 1.35
Molecular identification and targeting of colorectal cancer stem cells. Oncotarget (2010) 1.33
Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets. Exp Cell Res (2008) 1.33
Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One (2012) 1.32
Endothelial cell differentiation of human breast tumour stem/progenitor cells. J Cell Mol Med (2009) 1.30
Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia (2007) 1.29
Lectin microarrays identify cell-specific and functionally significant cell surface glycan markers. Glycobiology (2008) 1.28
Nonadhesive culture system as a model of rapid sphere formation with cancer stem cell properties. PLoS One (2012) 1.27
High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant. Oncotarget (2015) 1.27
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance. BMC Cancer (2012) 1.27
In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. PLoS One (2008) 1.27
Oncolytic reovirus effectively targets breast cancer stem cells. Mol Ther (2009) 1.27
TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. J Cell Physiol (2010) 1.27
Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res (2010) 1.26
Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res (2008) 1.26
The hypoxic tumor microenvironment: A driving force for breast cancer progression. Biochim Biophys Acta (2015) 1.25
Breast cancer stem cells. Int J Biochem Cell Biol (2012) 1.25
Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther (2007) 1.25
Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity. Clin Exp Metastasis (2008) 1.25
TGF-β-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition. Cell Rep (2013) 1.24
CD133 antigen expression in ovarian cancer. BMC Cancer (2009) 1.23
Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br J Cancer (2010) 1.23
Estrogen receptor α signaling regulates breast tumor-initiating cells by down-regulating miR-140 which targets the transcription factor SOX2. J Biol Chem (2012) 1.23
Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res (2010) 1.23
Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS One (2010) 1.23
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet (2005) 6.70
High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol (2006) 5.86
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell (2011) 5.06
A MicroRNA targeting dicer for metastasis control. Cell (2010) 4.81
Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol (2003) 4.22
Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A (2009) 4.19
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology (2004) 3.61
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol (2007) 3.38
Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst (2005) 3.26
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics (2008) 3.24
Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res (2007) 3.19
Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer (2006) 2.98
miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res (2009) 2.52
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol (2012) 2.36
Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell (2013) 2.35
Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg (2007) 2.30
SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res (2005) 2.20
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res (2004) 2.17
Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up. Ann Surg Oncol (2010) 2.14
Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: a randomized clinical trial (INT09/98). Cancer (2013) 2.07
Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res (2004) 1.99
30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ (2005) 1.97
Imatinib mesylate in chordoma. Cancer (2004) 1.94
TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J Clin Oncol (2010) 1.93
Phase II study of imatinib in advanced chordoma. J Clin Oncol (2012) 1.89
Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst (2004) 1.84
MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A (2006) 1.82
Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene (2004) 1.82
Rational design of shepherdin, a novel anticancer agent. Cancer Cell (2005) 1.74
Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci U S A (2005) 1.70
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res (2010) 1.68
PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors. Am J Surg Pathol (2008) 1.65
Chromosome band 17q21 in breast cancer: significant association between beclin 1 loss and HER2/NEU amplification. Genes Chromosomes Cancer (2010) 1.63
HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J Clin Oncol (2003) 1.61
Breast cancer stem cells: an overview. Eur J Cancer (2006) 1.61
A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up. Ann Surg (2005) 1.60
BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene (2004) 1.58
RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol (2003) 1.55
Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy (2011) 1.54
miR-21: an oncomir on strike in prostate cancer. Mol Cancer (2010) 1.54
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther (2009) 1.52
Challenges in projecting clustering results across gene expression-profiling datasets. J Natl Cancer Inst (2007) 1.52
Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer (2009) 1.51
Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis (2007) 1.50
Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat (2002) 1.49
KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res (2012) 1.49
Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. J Invest Dermatol (2009) 1.48
Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft. Cancer Biol Ther (2008) 1.47
Targeting survivin in cancer therapy. Expert Opin Ther Targets (2008) 1.47
Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res (2003) 1.45
Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases. Hum Mutat (2010) 1.45
Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res (2006) 1.44
Lack of SYT-SSX fusion transcripts in malignant peripheral nerve sheath tumors on RT-PCR analysis of 34 archival cases. Lab Invest (2002) 1.40
Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res (2009) 1.39
Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. Cancer Res (2005) 1.38
miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. Mol Cancer Res (2012) 1.38
Unusual myogenic and melanocytic differentiation of soft tissue pPNETs: an immunohistochemical and molecular study of 3 cases. Am J Surg Pathol (2010) 1.38
Italian performance in cancer research. Tumori (2009) 1.38
Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res (2006) 1.37
Survivin as a target for new anticancer interventions. J Cell Mol Med (2005) 1.37
Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells. J Invest Dermatol (2010) 1.35
Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res (2006) 1.35
Inflammation and cancer: the oncogene-driven connection. Cancer Lett (2008) 1.34
Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol Cancer Ther (2010) 1.29